AN2 Therapeutics Inc., a clinical-stage biopharmaceutical company, has announced the completion of a 200-patient observational study in acute melioidosis, funded by the National Institutes of Health. The study, which took place in acute hospital settings across three endemic regions, evaluated patients receiving the current standard of care: IV meropenem or ceftazidime. Results revealed a high mortality rate of nearly 40% by Day 90, underscoring the severity of the disease and the limitations of existing treatments. The data gained from this study will inform the design of a Phase 2 proof-of-concept trial for epetraborole, a novel therapeutic being developed by AN2 Therapeutics. This trial is expected to begin later this year, aiming to address the urgent need for more effective treatment options for melioidosis.